ATE497003T1 - Pharmazeutische zusammensetzung zur herstellung eines medikaments zur behandlung und/oder vorbeugung einer pathologie die mit einer obsessiven störung und/oder fettleibigkeit im zusammenhang steht - Google Patents

Pharmazeutische zusammensetzung zur herstellung eines medikaments zur behandlung und/oder vorbeugung einer pathologie die mit einer obsessiven störung und/oder fettleibigkeit im zusammenhang steht

Info

Publication number
ATE497003T1
ATE497003T1 AT03767876T AT03767876T ATE497003T1 AT E497003 T1 ATE497003 T1 AT E497003T1 AT 03767876 T AT03767876 T AT 03767876T AT 03767876 T AT03767876 T AT 03767876T AT E497003 T1 ATE497003 T1 AT E497003T1
Authority
AT
Austria
Prior art keywords
prevention
treatment
pharmaceutical composition
obesity
medication
Prior art date
Application number
AT03767876T
Other languages
English (en)
Inventor
Valerie Compan
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE497003T1 publication Critical patent/ATE497003T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT03767876T 2002-10-31 2003-10-31 Pharmazeutische zusammensetzung zur herstellung eines medikaments zur behandlung und/oder vorbeugung einer pathologie die mit einer obsessiven störung und/oder fettleibigkeit im zusammenhang steht ATE497003T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0213725A FR2846559B1 (fr) 2002-10-31 2002-10-31 Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle
PCT/FR2003/003262 WO2004042063A1 (fr) 2002-10-31 2003-10-31 Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle ou l'obesite

Publications (1)

Publication Number Publication Date
ATE497003T1 true ATE497003T1 (de) 2011-02-15

Family

ID=32104388

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03767876T ATE497003T1 (de) 2002-10-31 2003-10-31 Pharmazeutische zusammensetzung zur herstellung eines medikaments zur behandlung und/oder vorbeugung einer pathologie die mit einer obsessiven störung und/oder fettleibigkeit im zusammenhang steht

Country Status (12)

Country Link
US (3) US8859537B2 (de)
EP (1) EP1556489B1 (de)
JP (1) JP4852245B2 (de)
AT (1) ATE497003T1 (de)
AU (1) AU2003292310A1 (de)
CA (1) CA2503546C (de)
DE (1) DE60335892D1 (de)
DK (1) DK1556489T3 (de)
ES (1) ES2362092T3 (de)
FR (1) FR2846559B1 (de)
PT (1) PT1556489E (de)
WO (1) WO2004042063A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2846559B1 (fr) * 2002-10-31 2007-06-15 Centre Nat Rech Scient Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle
US20060204599A1 (en) * 2005-03-14 2006-09-14 Wheat Jared R Dietary supplement and method of using same
CA2808630A1 (en) 2010-08-19 2012-02-23 Buck Institute For Age Research Methods of treating mild cognitive impairment (mci) and related disorders
WO2019094596A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
FR3093419B1 (fr) * 2019-03-08 2021-06-18 Univ Grenoble Alpes Composition et procédé associé de mesure de l’observance thérapeutique
CA3136328A1 (en) * 2019-04-09 2020-10-15 The Trustees Of Columbia University In The City Of New York Prophylactic efficacy of serotonin 4 receptor agonists against stress
CN115581201A (zh) * 2022-08-26 2023-01-10 云南省农业科学院花卉研究所 以茎段为外植体诱导的二倍体月季f1-61的植株再生方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0624100B1 (de) * 1992-11-03 2000-05-03 Synaptic Pharmaceutical Corporation Für einen humanen serotoninrezeptor (5-ht4b) kodierende dns und ihre verwendung
US5472866A (en) * 1992-12-24 1995-12-05 Synaptic Pharmaceutical Corporation DNA encoding 5-HT4A serotonin receptors
AU1767997A (en) * 1996-02-15 1997-09-02 Janssen Pharmaceutica N.V. Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhibitors
WO2000064441A2 (en) * 1999-04-28 2000-11-02 Respiratorius Ab Compound for use as a medicament for treatment of disorders involving bronchocontraction
GB9913850D0 (en) * 1999-06-14 1999-08-11 Janssen Pharmaceutica Nv Cloning and expression of a novel receptor
FR2811989A1 (fr) * 2000-07-18 2002-01-25 Sanofi Synthelabo Derives de polyfluoroalkytriazole, leur preparation et leur application en therapeutique
FR2846559B1 (fr) * 2002-10-31 2007-06-15 Centre Nat Rech Scient Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle

Also Published As

Publication number Publication date
US20130274293A1 (en) 2013-10-17
FR2846559B1 (fr) 2007-06-15
US9168250B2 (en) 2015-10-27
DE60335892D1 (de) 2011-03-10
EP1556489B1 (de) 2011-01-26
ES2362092T3 (es) 2011-06-28
US20060116341A1 (en) 2006-06-01
WO2004042063A1 (fr) 2004-05-21
US8859537B2 (en) 2014-10-14
CA2503546C (fr) 2014-02-11
EP1556489A1 (de) 2005-07-27
JP4852245B2 (ja) 2012-01-11
FR2846559A1 (fr) 2004-05-07
AU2003292310A1 (en) 2004-06-07
JP2006520319A (ja) 2006-09-07
DK1556489T3 (da) 2011-05-16
US20090124592A1 (en) 2009-05-14
US8436021B2 (en) 2013-05-07
CA2503546A1 (fr) 2004-05-21
WO2004042063A8 (fr) 2005-08-11
PT1556489E (pt) 2011-05-31

Similar Documents

Publication Publication Date Title
BRPI0409523A (pt) método para o tratamento da dor neuropática, método de identificação de um composto e composição farmacêutica
ATE489365T1 (de) Verfahren und zwischenprodukte zur herstellung von (1r,2s,5s)-6,6-dimethyl-3-azabicycloä3,1,0 ühexan-2-carboxylaten oder salzen davon
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
WO2007125501A3 (en) Liquid compositions comprising phenylephrine and acetaminophen and their use for the treatment of respiratory illness
BRPI0513029A (pt) método para produzir uma proteìna de eritropoietina carbamilada, proteìna de eritropoietina carbamilada, composto, composição farmacêutica, métodos de tratamento de uma doença ou condição crÈnica, sub-crÈnica e aguda e de tratamento de uma doença do sistema nervoso central ou sistema nervoso periférico, e, uso de um composto
BRPI0514133A (pt) compostos de fórmula i, processo para a sua fabricação, composições farmacêuticas, método para o tratamento e/ou profilaxia de doença que são mediadas por inibidores de cetp e uso dos compostos de fórmula i
BRPI0606502A2 (pt) compostos; processo para a fabricação de compostos; composições farmacêuticas; método para o tratamento ou prevenção de doenças que são associadas com a modulação de receptores h3; método para o tratamento ou prevenção de obesidade em um ser humano ou animal; método de tratamento ou prevenção de diabetes tipo ii em um ser humano ou animal e usos de compostos
UY27993A1 (es) Derivados de 4-pirrolidino-fenil-bencil eter
ATE402211T1 (de) Verfahren zur herstellung von farblosen, lagerstabilen biuretgruppenhaltigen polyisocyanaten
DE602006009901D1 (de) Verfahren zur herstellung von 7-ethyl-10-hydroxycamptothecin
ATE497003T1 (de) Pharmazeutische zusammensetzung zur herstellung eines medikaments zur behandlung und/oder vorbeugung einer pathologie die mit einer obsessiven störung und/oder fettleibigkeit im zusammenhang steht
ATE390130T1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
BR0309406A (pt) Composição farmacêutica, processo de preparação, kit e métodos para tratamento de obesidade, utilização de composição e inibidor de lìpases, inibidor de lìpáses e glucomanan ou konjac e utilização dos mesmos e método de tratamento
BRPI0511714A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para tratar uma doença em um animal
DE69830079D1 (de) Verfahren zur verringerung des aox anteils in nassfesten harzen durch behandlung mit base
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
BRPI0510451A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas de ppar(delta) e/ou de ppar(alfa) e sua utilização
DE50210322D1 (de) Verfahren zur herstellung von extrakten aus pelargonium sidoides und/oder pelargonium reniforme
ATE502637T1 (de) Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum
BRPI0416580A (pt) sistema e método de tratamento de água
PL1716128T3 (pl) Podstawione związki 4,5,6,7-tetrahydrobenzotiazol-2-iloaminy
ATE460168T1 (de) Nicht-radioaktives strontiummittel zur behandlung von krebs
ATE407925T1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen
DE60311809D1 (de) Verfahren zur herstellung optisch reiner oder optisch angereicherter sulfoxidverbindungen einschliesslich amorphen esomeprazols und dessen salze
ATE259784T1 (de) Propanolaminotetraline, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende pharmazeutische zusammensetzungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1556489

Country of ref document: EP